Cortendo banks $26.4M; Bayer homes in on life sciences;

@FierceBiotech: ICYMI yesterday: $SNY drops the ax on 100 R&D staffers in Boston reorganization. Article | Follow @FierceBiotech

@JohnCFierce: J&J's R&D group crafts 3 new platforms to guide global drug development. Story | Follow @JohnCFierce

@DamianFierce: Things @AcordaNews has: 1. An Instagram account  2. A softball team called "COHEN'S CRUSHERS." Picture | Follow @DamianFierce

> Sweden's Cortendo hauled in $26.4 million in a private placement, cash that will help fund its Phase III trial of a drug for the rare Cushing's syndrome. More

> Bayer is reshaping its business to focus on life sciences, preparing to spin off its plastics arm over the next year. News

Medical Device News

@FierceMedDev: ICYMI yesterday: Intraocular lens maker Staar Surgical gets warning letter over its manufacturing practices. Story | Follow @FierceMedDev

@VarunSaxena2: UPDATED w/results of the sale: Trovagene raises $23M in follow-on share offering for urine-based cancer diagnostic. FierceDiagnostics article | Follow @VarunSaxena2

@EmilyWFierce: Scientists unveil new biomarker for early detection of dementia through blood test. Report | Follow @EmilyWFierce

> Bayer starts reorg as it explores sale of diabetes biz. More

> Invitae's $102M IPO stands alone as three med tech IPOs remain sidelined. Story

> Sanofi backs Europe's first remote clinical trial--for a smart glucose monitor. Article

Pharma News

@FiercePharma: Embattled Zoetis beats Q4 expectations, but tempers 2015 forecasts. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: In merely one week from THIS very moment, you could be listening to me moderate this super cool webinar: … Sign up! | Follow @CarlyHFierce

> Supplies of Roche's Tamiflu drained in HK as monthlong H3N2 outbreak hits. News

> Bayer rolls up its sleeves for major reorg after plastics unit departs. Story

> Hedge funder's first assault on iffy drug patents? Acorda's MS med Ampyra. Report

Vaccines News

> Advaxis inks pact with Incyte to test cervical cancer vaccine combo. Item

> Vaxxas scores $20M to develop needle-free vaccines. Article

> Serum Institute and Cipla in early merger talks. More

> GSK nabs pipeline prospects, conjugate vaccine tech with GlycoVaxyn buyout. Story

> GSK lays off 27 vaccine researchers in Montana. Report

Pharma Manufacturing News

> Genzyme biologics plant continues to pay off for Sanofi. Report

> Hospira recalls 60 lots of pain drug. Report

> Another doctor convicted for selling foreign-made drugs. Article

> GSK resolving shortage of Nicorette Lozenges. Story

> Report: 'Carrot and stick' needed to deal with drug shortages. More

Suggested Articles

A new, late-phase analysis of cholesterol-lowering inclisiran showed that it was able to cut LDL levels by 51% after nearly a year and a half.

The data were highly anticipated, especially since the two partners continued testing after the compound missed its endpoints in phase 2 studies.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.